GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » Short Interest

Coherus BioSciences (FRA:8C5) Short Interest


View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Coherus BioSciences's Short Interest

For the Biotechnology subindustry, Coherus BioSciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus BioSciences's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's Short Interest falls into.


Coherus BioSciences (FRA:8C5) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » Short Interest
Comparable Companies
MGNX CRBU TERN MLYS ICVX SPRY ERAS URGN ITOS AGEN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CHRS:USA
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Website
https://www.coherus.com
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Coherus BioSciences (FRA:8C5) Headlines

No Headlines